Cancer News and Research

Latest Cancer News and Research

Fibrogen reports FG-3019 Phase 2 study results for treatment of pancreatic cancer

Fibrogen reports FG-3019 Phase 2 study results for treatment of pancreatic cancer

AbbVie releases preliminary results from ABT-414 Phase I study in patients with recurrent or unresectable GBM

AbbVie releases preliminary results from ABT-414 Phase I study in patients with recurrent or unresectable GBM

ASCO: Biothera to present phase 2 study data on predictive serum biomarker for NSCLC

ASCO: Biothera to present phase 2 study data on predictive serum biomarker for NSCLC

Castle Biosciences reports study results from DecisionDx-EC multi-analyte test for esophageal cancer

Castle Biosciences reports study results from DecisionDx-EC multi-analyte test for esophageal cancer

Amgen presents extended analysis of PEAK study data at ASCO

Amgen presents extended analysis of PEAK study data at ASCO

New cancer panel holds promise in detection of previously undetected viral, cancer mutations

New cancer panel holds promise in detection of previously undetected viral, cancer mutations

New software tool helps identify genetic mutations linked to increased risk for cancer

New software tool helps identify genetic mutations linked to increased risk for cancer

Goserelin can help reduce risk of early menopause in young women with breast cancer

Goserelin can help reduce risk of early menopause in young women with breast cancer

HCV reactivation may not worsen survival outcomes for lymphoma patients with HIV

HCV reactivation may not worsen survival outcomes for lymphoma patients with HIV

New data highlights molecular profiling in guiding treatment of patients with gynecologic malignancies

New data highlights molecular profiling in guiding treatment of patients with gynecologic malignancies

ASCO Expert Panel develops treatment guidelines for cancer-related fatigue

ASCO Expert Panel develops treatment guidelines for cancer-related fatigue

UTHealth’s professor receives highly competitive Fulbright-Nehru Scholarship Award

UTHealth’s professor receives highly competitive Fulbright-Nehru Scholarship Award

ASCO: DelMar presents interim data from VAL-083 clinical trial in refractory GBM

ASCO: DelMar presents interim data from VAL-083 clinical trial in refractory GBM

Eisai announces results from Phase III SELECT trial of lenvatinib evaluating PFS in patients with RR-DTC

Eisai announces results from Phase III SELECT trial of lenvatinib evaluating PFS in patients with RR-DTC

OncLive announces 2014 Giants of Cancer Care

OncLive announces 2014 Giants of Cancer Care

ASCO honors St. Jude researcher with 2014 Pediatric Oncology Award

ASCO honors St. Jude researcher with 2014 Pediatric Oncology Award

New data on Gilotrif and investigational compounds to be presented at 50th ASCO annual meeting

New data on Gilotrif and investigational compounds to be presented at 50th ASCO annual meeting

Promedior reports positive preliminary data from PRM-151 Phase 2 trial for myelofibrosis

Promedior reports positive preliminary data from PRM-151 Phase 2 trial for myelofibrosis

Angiochem presents data on ANG1005 paclitaxel-peptide drug conjugate at 50th ASCO annual meeting

Angiochem presents data on ANG1005 paclitaxel-peptide drug conjugate at 50th ASCO annual meeting

Morphogenesis announces publication of new book, Cancer Vaccines: Methods and Protocols

Morphogenesis announces publication of new book, Cancer Vaccines: Methods and Protocols

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.